Vericel Corporation (VCEL)
NASDAQ: VCELHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VCEL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.94B
- P/E (TTM)
- 89.88
- Forward P/E
- 61.06
- EPS (TTM)
- $0.64
- Dividend yield
- None
- 52-week range
- 28.95 – 59.75
- Day range
- 57.33 – 59.49
- Volume / Avg
- 582.32K / 664.34K
- Beta
- —
- Shares outstanding
- 51.03M
52-week range
VCEL stock today
On Nov 20, VCEL ended the session at $57.52, shedding $0.74 (1.27%), versus the S&P 500's 3.70% decline. At this level, VCEL sits near the top of its 52-week range of $28.95 to $59.75: 3.7% below the high, set on Nov 11, 2026 and 98.7% above the low. VCEL is up 59.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 45.3%.
Vericel trades at 89.9x its trailing twelve-month earnings per share of $0.64. Its forward P/E of 61.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Vericel
Company profileVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Dominick C. Colangelo Esq.
- Headquarters
- Burlington, MA
- Employees
- 398
- Website
- vcel.com
Financial highlights
Full financialsIn fiscal 2025, Vericel generated $276.3 million in revenue, up 16.5% from fiscal 2024, its 12th consecutive year of revenue growth. Net income was $16.5 million (+59.4% year over year), for a net margin of 6.0% versus a median of -1.6% in the prior 5 years. Gross margin was 74.4% (up from 72.6%) and operating margin 4.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $276.26M | $237.22M | $197.52M | $164.37M | $156.18M |
| Growth | +16.45% | +20.10% | +20.17% | +5.24% | +25.77% |
| Net income | $16.52M | $10.36M | $-3.18M | $-16.71M | $-7.47M |
| EPS (diluted) | $0.32 | $0.20 | $-0.07 | $-0.35 | $-0.16 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$65.43+13.75%
- Strong buy 0
- Buy 7
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $0.27 vs $0.02
- Surprise
- +1250.00%
VCEL news
All VCEL news- REGN Gets FDA Nod for Livsayis in Generalized Myasthenia GravisNasdaqREGN, ALNY, VCEL, ETON
- NVS Gets FDA Nod for Cosentyx in Adults With Polymyalgia RheumaticaNasdaqNVS, VCEL, ETON
- J&J to Boost Ophthalmology Pipeline With $2.2B Ollin AcquisitionNasdaqJNJ, COLL, VCEL
- Novartis' Cosentyx Gets Positive CHMP Opinion for Adolescents With HSNasdaqNVS, COLL, VCEL, KROS
- Vericel to Present at the Stephens Annual Investment Conference on Wednesday, November 18, 2026GlobeNewswire
- Pfizer Secures Up to $1.5B Funding From Blackstone for Obesity ProgramNasdaqPFE, COLL, VCEL, AMRX
- Vericel Q3 Earnings Call HighlightsNasdaq
- Vericel forecasts $344M-$346M 2026 revenue while raising adjusted EBITDA margin guidance to ~28%Seeking Alpha
Vericel peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DNLIDenali Therapeutics Inc. | 18.45 | +1.37% | $2.96B | vs VCEL |
| ADMAADMA Biologics Inc | 13.17 | -1.27% | $2.92B | vs VCEL |
| IOVAIovance Biotherapeutics Inc. | 6.90 | -5.61% | $3.19B | vs VCEL |
| RLAYRelay Therapeutics Inc. | 16.12 | +1.32% | $3.56B | vs VCEL |
| TARSTarsus Pharmaceuticals Inc. | 73.01 | -6.00% | $3.60B | vs VCEL |
| BEAMBeam Therapeutics Inc. | 20.90 | -0.19% | $2.16B | vs VCEL |
| CRSPCRISPR Therapeutics AG | 39.10 | +0.44% | $3.79B | vs VCEL |
| BCRXBioCryst Pharmaceuticals Inc. | 7.22 | -1.37% | $1.86B | vs VCEL |
Indexes, lists and sector
Vericel stock FAQ
What is Vericel's stock price today?
VCEL last traded at $57.52 as of Nov 20, 4:00 PM EST, down 1.27% on the day. Prices are delayed at least 15 minutes.
Does Vericel pay a dividend?
No. Vericel does not currently pay a regular cash dividend.
What is VCEL's P/E ratio?
VCEL trades at a trailing P/E ratio of 89.88 and a forward P/E of 61.06.
Who is Vericel's CEO?
Mr. Dominick C. Colangelo Esq. is the chief executive officer of Vericel Corporation, which has about 398 employees.
Has VCEL ever split its stock?
Yes. The most recent VCEL stock split was a 1-for-20 split on Oct 16, 2013, one of 2 splits on record.
What is the VCEL 52-week high?
The 52-week high for VCEL is $59.75 and the 52-week low is $28.95. The stock is currently 3.7% below its high.